Anti-tuberculosis treatment strategies and drug development: challenges and priorities
VA Dartois, EJ Rubin - Nature Reviews Microbiology, 2022 - nature.com
Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …
biological uncertainties remain and hamper progress. However, owing to collaborative …
[HTML][HTML] The pipeline of new molecules and regimens against drug-resistant tuberculosis
TA Black, UK Buchwald - Journal of Clinical Tuberculosis and Other …, 2021 - Elsevier
The clinical development and regulatory approval of bedaquiline, delamanid and
pretomanid over the last decade brought about significant progress in the management of …
pretomanid over the last decade brought about significant progress in the management of …
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a …
Background Bedaquiline improves outcomes of patients with rifampicin-resistant and
multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this …
multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this …
Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid, and …
H Huerga, U Khan, M Bastard… - Clinical Infectious …, 2022 - academic.oup.com
Background Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-
drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially …
drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially …
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial
L Guglielmetti, E Ardizzoni, M Atger, E Baudin… - Trials, 2021 - Springer
Background Treatment of multidrug-and rifampin-resistant tuberculosis (MDR/RR-TB) is
expensive, labour-intensive, and associated with substantial adverse events and poor …
expensive, labour-intensive, and associated with substantial adverse events and poor …
Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children
H Zhu, X Zhou, Z Zhuang, L Li, J Bi… - Frontiers in Cellular and …, 2023 - frontiersin.org
Tuberculosis (TB) is a major public health problem, with nearly 10 million new cases and
millions of deaths each year. Around 10% of these cases are in children, but only a fraction …
millions of deaths each year. Around 10% of these cases are in children, but only a fraction …
Cycloserine and linezolid for tuberculosis meningitis: pharmacokinetic evidence of potential usefulness
RR Kempker, AGC Smith, T Avaliani… - Clinical Infectious …, 2022 - academic.oup.com
Background The ability of antituberculosis drugs to cross the blood–brain barrier and reach
the central nervous system is critical to their effectiveness in treating tuberculosis meningitis …
the central nervous system is critical to their effectiveness in treating tuberculosis meningitis …
[HTML][HTML] Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis
L Fu, T Weng, F Sun, P Zhang, H Li, Y Li, Q Yang… - International Journal of …, 2021 - Elsevier
Background Multidrug-resistant tuberculosis (MDR-TB) patients have been suffering long,
ineffective, and toxic treatment until short-course injectable-free regimens emerged …
ineffective, and toxic treatment until short-course injectable-free regimens emerged …
Assessing prolongation of the corrected QT interval with bedaquiline and delamanid coadministration to predict the cardiac safety of simplified dosing regimens
L Tanneau, MO Karlsson… - Clinical …, 2022 - Wiley Online Library
Delamanid and bedaquiline are two drugs approved to treat drug‐resistant tuberculosis, and
each have been associated with corrected QT interval (QTc) prolongation. We aimed to …
each have been associated with corrected QT interval (QTc) prolongation. We aimed to …
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications
ML Rich, U Khan, C Zeng, A LaHood… - … of Tuberculosis and …, 2023 - ingentaconnect.com
BACKGROUND: Evidence of the effectiveness of the WHO-recommended design of longer
individualized regimens for multidrug-or rifampicin-resistant TB (MDR/RR-TB) is limited …
individualized regimens for multidrug-or rifampicin-resistant TB (MDR/RR-TB) is limited …